Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HLA-A2 p53:264-272 vaccine |
| Synonyms | |
| Therapy Description |
HLA-A2 p53:264-272 vaccine is a peptide vaccine consists of the peptide of aa264 to aa272 of wild-type Tp53, which may induce immune response against tumor cells (PMID: 15608425). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HLA-A2 p53:264-272 vaccine | p53 Vaccine 5 | HLA-A2 p53:264-272 vaccine is a peptide vaccine consists of the peptide of aa264 to aa272 of wild-type Tp53, which may induce immune response against tumor cells (PMID: 15608425). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| TP53 over exp | ovarian cancer | predicted - sensitive | HLA-A2 p53:264-272 vaccine | Phase I | Actionable | In a Phase I trial, the HLA-A2 p53:264-272 vaccine demonstrated safety and preliminary efficacy in patients with TP53 overexpressing ovarian cancer, resulting in a progression-free survival of 5.5 months and an overall survival of 40.4 months (PMID: 21927947). | 21927947 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|